![The largest clinical trial to-date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure – City of Hope](https://oncodaily.com/pub/uploads/2024/01/download-40-1280x669.jpg)
The largest clinical trial to-date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure – City of Hope
City of Hope shared a post on LinkedIn:
“A team of physicians led by Saro H. Armenian, D.O., M.P.H., Barron Hilton Chair in Pediatrics at City of Hope Children’s Cancer Center, have conducted the largest clinical trial to-date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure. The study was conducted in cooperation with the Children’s Oncology Group.
The findings published in The Lancet Oncology show that carvedilol, the blood vessel relaxing medication, is safe for childhood cancer survivors to take and may improve important markers of heart injury sustained as a result of chemotherapy exposure.
‘The growing number of childhood cancer survivors makes the development of early interventions imperative. Just helping children survive cancer isn’t enough. We also need to optimize patients’ health so that they don’t have to face life-threatening side effects decades after they are cancer free,’ said Armenian.”
Source: City of Hope/LinkedIn